The ACO Paradox

As of today, we are still awaiting the CMS regulations on Health Reform’s Accountable Care Organizations. I’ve made a couple of postings on ACOs in the past. I reiterated the importance of process measures in pay-for-performance schemes, and I scoffed at investor-owned hospitals’ proposal of cherry-picking patients for ACO membership. Here, I’d like to discuss what I’ll call the ACO Paradox.

There are two main components of the Medicare pay-for-performance program (Sec. 3022) for qualified Accountable Care Organizations (ACO), according to the Health Reform Law. First, the Medicare Shared Savings program is designed to reward ACOs for decreasing Medicare fee-for-service costs of their assigned members. If the ACO’s adjusted costs for Medicare parts A & B in the measurement year are less than the benchmark (a 3 year per-beneficiary average), then the ACO and Medicare will share in that cost difference. Second, to qualify for Shared Savings bonus, the ACO must meet quality performance standards (soon to be proposed by CMS).

It makes sense for Medicare to join the costs savings with improved quality. Both are key aims of Health Reform (expanded coverage being another). However, will the ACOs be able to achieve both cost savings and improved quality simultaneously in the measurement year?

The conventional wisdom in healthcare states that increased quality of care will save money in the short-term by reducing high-cost services, such as inpatient care. However, some QOC measures have been shown to be statistically related to increased near-term healthcare costs. For example, a recent study found that improved adherence to antiretroviral regimens used to fight HIV was associated with an increase in total medical costs. Riegal et al. (2000) have posited that the positive relationship of QOC measures to increased near-term future costs is probably due to improved access to needed services.

This isn’t to say that cost savings are not possible with improved quality. It may be that some measures do actually save in the short-term, while others do not. Or maybe it is that some (or all) quality measures save money in the long-term – 5, 10 or 20 years in the future.

So, what if the quality measures that CMS chooses are actually related to increased costs in the measurement period? What if some quality measures are not worth the investment for ACOs? In other words, will there be any Medicare cost savings to be shared in the short-term? Is there an ACO Paradox?

Perhaps Medicare should consider extending the ACO quality measurement and shared savings period to reflect the near-term investment required to produce decreased healthcare cost in the long-term.